Nykode Therapeutics ASA
NYKD.OLDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
VB10.16 Immunotherapy (DNA vaccine)
High Grade Cervical Intraepithelial Neoplasia
VB10.2129
COVID-19
VB10.NEO
Locally Advanced or Metastatic Solid Tumours
VB10.16
Cervical Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VB10.16 Immunotherapy (DNA vaccine) | Phase 2 | High Grade Cervical Intraepithelial Neoplasia | - | - |
VB10.2129 | Phase 2 | COVID-19 | - | - |
VB10.NEO | Phase 2 | Locally Advanced or Metastatic Solid Tumours | - | - |
VB10.16 | Phase 2 | Cervical Cancer | - | - |
Frequently asked questions
What is in Nykode Therapeutics ASA's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Nykode Therapeutics ASA's (NYKD.OL) pipeline across Phase 2. Its lead program is VB10.16 Immunotherapy (DNA vaccine) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nykode Therapeutics ASA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nykode Therapeutics ASA (NYKD.OL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NYKD.OL biotech catalysts?→
Add NYKD.OL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nykode Therapeutics ASA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.